Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease

May 20, 2022 updated by: Shao-Ping Nie, Beijing Anzhen Hospital

A Multi-center, Prospective, Registry Study to Estimate the Current Status of Care for Patients With Coronary Artery Disease

The study will estimate the current status of care for participants with coronary artery disease

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

100000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
      • Beijing, China
        • Recruiting
        • Beijing Anzhen Hospital
        • Contact:
          • Chaoyang Wu
          • Phone Number: +86-10-64456214

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Hospitalized patients with coronary artery disease

Description

Inclusion Criteria:

  • Hospitalized patients with discharge diagnosis as coronary artery disease (including atherosclerosis or non-athrosclerosis)

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The overall composite of 10 performance measures for CAD care
Time Frame: Duration of hospital stay, an expected average of 1 week

Performance measures for CAD care including:

Proportion of patients received fibrinolytic therapy within 30 mins (STEMI) Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI) Proportion of patients received reperfusion therapy (STEMI, high or moderate risk NSTE-ACS) Proportion of patients with aspirin prescribed at discharge Proportion of patients with P2Y12 inhibitors prescribed at discharge Proportion of patients with beta-blocker prescribed at discharge Proportion of patients with statin prescribed at discharge Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge Proportion of patients received evaluation of left ventricular systolic function Proportion of patients with a diagnosed non-obstructive coronary artery disease at discharge
Duration of hospital stay, an expected average of 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Anzhen Hospital

Investigators

  • Principal Investigator: Shaoping Nie, MD, PhD, Beijing Anzhen Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 17, 2022

Primary Completion (Anticipated)

December 30, 2027

Study Completion (Anticipated)

December 30, 2028

Study Registration Dates

First Submitted

April 13, 2022

First Submitted That Met QC Criteria

April 13, 2022

First Posted (Actual)

April 20, 2022

Study Record Updates

Last Update Posted (Actual)

May 26, 2022

Last Update Submitted That Met QC Criteria

May 20, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCCMRC202201_001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe